Harrow Inc

HROW03 Dec 2024
Healthcare
$41.38
0.00 (0.00%)
Lowest Today
$40
Highest Today
$42.13
Today’s Open
$41.38
Prev. Close
$41.91
52 Week High
$59.23
52 Week Low
$9.13
To Invest in Harrow Inc

Harrow Inc

Healthcare
HROW03 Dec 2024
0.00 (0.00%)
1M
3M
6M
1Y
5Y
Low
$40
Day’s Range
High
$42.12
40
52 Week Low
$9.13
52-Week Range
52 Week High
$59.23
9.13
1 Day
-
1 Week
-0.64%
1 month return
-5.98%
3 month return
+3.26%
6 month return
+135.28%
1 Year return
+354.2%
3 Years return
+313.55%
5 Years return
+574.35%
10 Years return
-
Institutional Holdings
Opaleye Management Inc
11.2
Private Capital Management, LLC
6.08
BlackRock Inc
6.03
Vanguard Group Inc
5.24
Vanguard Total Stock Mkt Idx Inv
2.8
iShares Russell 2000 ETF
2.21
Geode Capital Management, LLC
2.03

Market Status

Fundamentals
Market Cap
1512.56 mln
PB Ratio
26.09
PE Ratio
0
Enterprise Value
1636.02 mln
Total Assets
312.16 mln
Volume

Company Financials

Fund house & investment objective

Company Information
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract surgery; VIGAMOX, a fluoroquinolone antibiotic eye drop for the treatment of bacterial conjunctivitis; MAXIDEX and FLAREX, a steroid eye drop for steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe and the eye; TRIESENCE, a steroid injection for the treatment of ophthalmic diseases and for visualization during vitrectomy; and NATACYN, a sterile, antifungal drug for the treatment of fungal blepharitis, conjunctivitis, and keratitis. In addition, it offers TOBRADEX ST, a tobramycin and dexamethasone ophthalmic suspension; VERKAZIA cyclosporine ophthalmic emulsion; NEVANAC, a non-steroidal, anti-inflammatory eye drop; and FRESHKOTE preservative free (PF) is a lubricant eye drop. Further, the company has collaboration with Asembia to enhance provider and patient experience through nationwide digital services and hub support for harrow's branded eyecare products. The company was formerly known as Harrow Health, Inc. and changed its name to Harrow, Inc. in September 2023. Harrow, Inc. was founded in 1998 and is headquartered in Nashville, Tennessee.
Organisation
Harrow Inc
Employees
315
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Mark L. Baum J.D.
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step

Click here to see your activities